论文部分内容阅读
目的:研究不同剂量骨化三醇治疗血液透析患者继发性甲状旁腺功能亢进的有效性和安全性。方法:选择80例血液透析患者,血清甲状旁腺激素(iPTH)>300pg/mL,血钙<2.75mmol/L,血磷<2.26mmol/L,随机分为冲击治疗组和常规治疗组,记录血钙、血磷、钙磷乘积、血iPTH的变化。结果:观察治疗20周后,冲击治疗组iPTH水平显著降低(P<0.05),达到目标范围。2例患者出现高钙血症,无一例发生持续性高钙血症,无一例钙磷乘积大于5.65mmol 2/L2。结论:合理剂量的骨化三醇冲击治疗可有效控制血液透析患者继发性甲状旁腺功能亢进,安全性良好。
Objective: To study the efficacy and safety of different doses of calcitriol in the treatment of hemodialysis patients with secondary hyperparathyroidism. Methods: Eighty patients with hemodialysis were enrolled in this study. Serum parathyroid hormone (iPTH)> 300pg / mL, serum calcium <2.75mmol / L and blood phosphorus <2.26mmol / L were randomly divided into the treatment group and the conventional treatment group Blood calcium, phosphorus, calcium and phosphorus products, blood iPTH changes. Results: Observed after 20 weeks of treatment, the impact of iPTH levels were significantly reduced (P <0.05), reaching the target range. Two patients had hypercalcemia, and none had persistent hypercalcemia. None of the patients had a calcium-phosphorus product greater than 5.65 mmol 2 / L 2. Conclusion: A reasonable dosage of calcitriol treatment can effectively control secondary hyperparathyroidism in hemodialysis patients with good safety.